PRICE POSITIONING ASSESSMENT FOR AN ORPHAN DRUG INDICATED IN LIGHT CHAIN AMYLOIDOSIS
To define the pricing strategy to be adopted for a first-in-class, disease-modifying agent for the treatment of light chain amyloidosis.
To design a “Roadmap to market access” in the EU-4 documenting P&R requirements, formal steps, tasks & timelines, and investments the company should plan to launch.
- Review of past analogue researches and pricing assessments.
- Qualitative and quantitative pricing research through KOL, payer and market access experts interviews, after developing relevant target product profiles, discussion guidelines and interview materials.
- Per country analysis of interview findings and cross-country determination of optimal price corridor and launch sequence.
A country-specific price strategy was elaborated and presented together with key value perception parameters emerged from the analysis, market share and profit impact for the product in object across a variety of trial results and indication launch scenarios.